NLS Pharmaceutics Unveils Innovative Research at 2025 ASCP Annual Meeting
In a recent announcement, NLS Pharmaceutics Ltd., a clinical-stage biopharmaceutical company based in Switzerland, revealed its participation in the upcoming 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP). Set to take place from May 27 to May 30, 2025, in Scottsdale, Arizona, this esteemed conference will provide a platform to showcase cutting-edge advancements in neuropsychopharmacology. NLS Pharmaceutics is set to present three pivotal research abstracts that highlight innovative approaches to treat central nervous system disorders.
NLS Pharmaceutics will present the following studies at the ASCP Annual Meeting:
1. Evaluating the Effects of Mazindol on Fentanyl Dependence in Animal Models (Study KO-943)
This research investigates the therapeutic potential of Mazindol ER, a triple monoamine reuptake inhibitor with additional activity targeting 5-HT1A, MOP, and OX2R receptors. The study focuses on the impact of Mazindol ER on fentanyl dependence in preclinical models, highlighting its ability to reduce both reward-seeking behaviors and withdrawal symptoms. The findings suggest that Mazindol ER could serve as a promising non-opioid alternative for managing fentanyl addiction, which is a significant concern in public health today.
2. Non-Sulfonamide Dual Orexin Receptor Agonists: Preliminary Results of AEX-41 and AEX-2 in a Mouse Model of Narcolepsy
This abstract presents encouraging initial findings regarding two novel dual orexin receptor agonists, AEX-41 and AEX-2, evaluated in a mouse model of narcolepsy. These compounds are noted for their wake-promoting properties without the adverse metabolic effects often associated with traditional stimulant medications. This places AEX-41 and AEX-2 as leading candidates for the treatment of narcolepsy and related hypersomnolence disorders.
3. Comprehensive Multitarget Strategy for Managing Diabetes-Associated Neurological and Sleep Disorders (DANS)
This innovative study introduces a novel pharmacological platform aimed at addressing cognitive and sleep disorders linked to diabetes. By integrating dual orexin receptor agonists, neuropeptide-based preconditioning, and metabolic modulators, this research tackles the complex interplay of neuroinflammation, β-cell dysfunction, and circadian rhythm disruptions affecting diabetic patients.
Reflecting on their contributions to the ASCP Annual Meeting, Dr. Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics, emphasized the company's dedication to advancing clinical research in neuropsychopharmacology. Dr. Konofal stated, "We are thrilled to present our innovative solutions ranging from Mazindol ER for fentanyl dependence to dual orexin receptor agonists targeting narcolepsy and a unique multitarget approach for diabetes-related cognitive and sleep disorders. Our participation in this platform demonstrates our ongoing commitment to addressing critical unmet medical needs in the domains of addiction medicine, sleep disorders, and cognitive health."
Founded in Switzerland, NLS Pharmaceutics Ltd. is dedicated to developing state-of-the-art therapies for rare and complex CNS disorders. The company collaborates with renowned scientists and pharmaceutical organizations to deliver innovative solutions in addiction medicine, sleep disorders, and cognitive dysfunction. NLS Pharmaceutics highlights the importance of their research in contributing to the future of neuropsychopharmacology and remains focused on delivering effective treatments that could significantly enhance patient outcomes.
For more information about NLS Pharmaceutics and their work, visit their official website at www.nlspharma.com. This announcement underscores the vibrant and ongoing exploration in the field of neuropsychopharmacology, especially as various new therapies are investigated to meet the needs of patients dealing with CNS disorders.
Research Abstracts Overview
NLS Pharmaceutics will present the following studies at the ASCP Annual Meeting:
1. Evaluating the Effects of Mazindol on Fentanyl Dependence in Animal Models (Study KO-943)
This research investigates the therapeutic potential of Mazindol ER, a triple monoamine reuptake inhibitor with additional activity targeting 5-HT1A, MOP, and OX2R receptors. The study focuses on the impact of Mazindol ER on fentanyl dependence in preclinical models, highlighting its ability to reduce both reward-seeking behaviors and withdrawal symptoms. The findings suggest that Mazindol ER could serve as a promising non-opioid alternative for managing fentanyl addiction, which is a significant concern in public health today.
2. Non-Sulfonamide Dual Orexin Receptor Agonists: Preliminary Results of AEX-41 and AEX-2 in a Mouse Model of Narcolepsy
This abstract presents encouraging initial findings regarding two novel dual orexin receptor agonists, AEX-41 and AEX-2, evaluated in a mouse model of narcolepsy. These compounds are noted for their wake-promoting properties without the adverse metabolic effects often associated with traditional stimulant medications. This places AEX-41 and AEX-2 as leading candidates for the treatment of narcolepsy and related hypersomnolence disorders.
3. Comprehensive Multitarget Strategy for Managing Diabetes-Associated Neurological and Sleep Disorders (DANS)
This innovative study introduces a novel pharmacological platform aimed at addressing cognitive and sleep disorders linked to diabetes. By integrating dual orexin receptor agonists, neuropeptide-based preconditioning, and metabolic modulators, this research tackles the complex interplay of neuroinflammation, β-cell dysfunction, and circadian rhythm disruptions affecting diabetic patients.
NLS Pharmaceutics' Commitment to Clinical Research
Reflecting on their contributions to the ASCP Annual Meeting, Dr. Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics, emphasized the company's dedication to advancing clinical research in neuropsychopharmacology. Dr. Konofal stated, "We are thrilled to present our innovative solutions ranging from Mazindol ER for fentanyl dependence to dual orexin receptor agonists targeting narcolepsy and a unique multitarget approach for diabetes-related cognitive and sleep disorders. Our participation in this platform demonstrates our ongoing commitment to addressing critical unmet medical needs in the domains of addiction medicine, sleep disorders, and cognitive health."
Background on NLS Pharmaceutics
Founded in Switzerland, NLS Pharmaceutics Ltd. is dedicated to developing state-of-the-art therapies for rare and complex CNS disorders. The company collaborates with renowned scientists and pharmaceutical organizations to deliver innovative solutions in addiction medicine, sleep disorders, and cognitive dysfunction. NLS Pharmaceutics highlights the importance of their research in contributing to the future of neuropsychopharmacology and remains focused on delivering effective treatments that could significantly enhance patient outcomes.
For more information about NLS Pharmaceutics and their work, visit their official website at www.nlspharma.com. This announcement underscores the vibrant and ongoing exploration in the field of neuropsychopharmacology, especially as various new therapies are investigated to meet the needs of patients dealing with CNS disorders.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.